Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Adverse Event Data Clouds Potential Fluoroquinolone Label Changes

Executive Summary

Advisory committee unsure how to describe fluoroquinolone-associated disability in labeling.

You may also be interested in...

Fluoroquinolones Get New Safety Labeling, But Not A REMS

Risk of disabling, potentially permanent serious side effects that can occur together will be added to Cipro, Levaquin labels along with limitation against use for some self-limiting conditions unless there are no alternative treatments.

Fluoroquinolones Need REMS With Communication Plan, AdCom Says

Overwhelming votes against existing labels for the antibiotics likely means sponsors and FDA have some safety planning to do.

Fluoroquinolones: Is Another FDA Safety Step Needed?

Joint advisory committee meeting will discuss post-marketing safety data, including adverse events across organ systems.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts